We are live on ! Find out more
OTLK icon

Outlook Therapeutics
OTLK

87 hedge funds and large institutions have $51.1M invested in Outlook Therapeutics in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

72% more capital invested

Capital invested by funds: $29.7M → $51.1M (+$21.4M)

71% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 7

55% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 20

6% more funds holding

Funds holding: 82 → 87 (+5)

0.04% more ownership

Funds ownership: 0.53% → 0.57% (+0.04%)

Holders
87
Holders Change
+5
Holders Change %
+6.1%
% of All Funds
1.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
31
Reduced
20
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$1.57M
2
State Street
State Street
Massachusetts
+$998K
3
Squarepoint
Squarepoint
New York
+$343K
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$250K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$188K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$507K
2
N
Nuveen
North Carolina
-$350K
3
VF
Vista Finance
Missouri
-$237K
4
GCP
GSA Capital Partners
United Kingdom
-$107K
5
Citadel Advisors
Citadel Advisors
Florida
-$98.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$16M +$1.57M +57,419 +14%
Vanguard Group
2
Vanguard Group
Pennsylvania
$10.7M +$188K +6,879 +2%
State Street
3
State Street
Massachusetts
$4.79M +$998K +36,596 +36%
Geode Capital Management
4
Geode Capital Management
Massachusetts
$4.73M +$250K +9,156 +7%
LA
5
LVW Advisors
New York
$3.02M – – –
Northern Trust
6
Northern Trust
Illinois
$2.18M +$72.1K +2,646 +4%
N
7
Nuveen
North Carolina
$1.04M -$350K -12,835 -30%
Bank of New York Mellon
8
Bank of New York Mellon
New York
$824K +$71.2K +2,612 +12%
Charles Schwab
9
Charles Schwab
California
$726K +$6.6K +242 +1%
LNC
10
Lincoln National Corp
Pennsylvania
$557K +$172K +6,300 +65%
Squarepoint
11
Squarepoint
New York
$551K +$343K +12,572 +386%
Wells Fargo
12
Wells Fargo
California
$354K +$47.5K +1,742 +21%
Morgan Stanley
13
Morgan Stanley
New York
$350K +$55.2K +2,024 +25%
RhumbLine Advisers
14
RhumbLine Advisers
Massachusetts
$338K +$21.8K +799 +9%
MCA
15
MSH Capital Advisors
Arizona
$329K +$165K +6,045 +177%
FMC
16
First Merchants Corp
Indiana
$260K – – –
Millennium Management
17
Millennium Management
New York
$250K -$507K -18,587 -72%
Goldman Sachs
18
Goldman Sachs
New York
$231K +$84K +3,080 +87%
JP Morgan Chase
19
JP Morgan Chase
New York
$210K +$2.45K +90 +2%
AllianceBernstein
20
AllianceBernstein
Tennessee
$208K +$103K +3,776 +172%
AA
21
Ancora Advisors
Ohio
$189K – – –
LPL Financial
22
LPL Financial
California
$176K – – –
MIM
23
MetLife Investment Management
New Jersey
$145K – – –
AIG
24
American International Group
New York
$130K +$27 +1 +0%
GCM
25
Gables Capital Management
Florida
$116K – – –
1
2 3 4

OTLK Hedge Fund Activity: Q2 2023 in Review

87 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q2 2023, worth a combined $51.1M — up 72% from $29.7M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new OTLK positions and 7 closed out — a net gain of 5 holders — while 31 added to existing stakes and 20 trimmed.

The largest buyer was BlackRock, adding an estimated $1.57M. The largest seller was Millennium Management, cutting an estimated $507K.

  • 87 institutional investors held Outlook Therapeutics (OTLK) as of Q2 2023, up from 82 in Q1 2023.
  • Funds reported $51.1M of Outlook Therapeutics stock for Q2 2023, up 72% quarter-over-quarter.
  • 12 funds opened new Outlook Therapeutics positions in Q2 2023 and 7 closed out, a net change of +5 holders.
  • The largest Outlook Therapeutics buyer in Q2 2023 was BlackRock, an estimated $1.57M added.
  • The largest Outlook Therapeutics seller in Q2 2023 was Millennium Management, an estimated $507K sold.

Based on aggregated 13F filings for Q2 2023.